M.V. LOMONOSOV MOSCOW STATE UNIVERSITY FACULTY OF BASIC MEDICINE COMPARISON OF POLY- CHEMOTHERAPY (CVD regimen) & THE SAME CHEMOTHERAPY (CT) PLUS INTERFERON-α2a IN METASTATIC MELANOMA Student: Dr. Kyaw Thura Zaw Scientific Supervisor : Prof. Dr. Lev Demidov N.N. BLOKHIN CANCER RESEARCH CENTRE Moscow ,2010
Malignant melanoma is a neoplasm of melanocytes or of the cells that develop from melanocytes.
Melanoma is showing a rapid worldwide rise in incidence, with a yearly increase of about 5% and a frequent occurrence in young adults . Even though surgery represents the cure in the early phase of disease, the prognosis in patients with metastatic melanoma remains very poor, with a median survival of about 6–9 months .
Frequency : Queensland, Australia, has the highest incidence of melanoma in the world, approximately 57 cases / 100,000 people / year. Israel also has one of the highest incidences, approximately 40 cases / 100,000 people annually.
Incidence : Increasing rapidly worldwide, and faster rate than that of any other cancer except lung cancer in women. Melanoma is notorious for affecting young and middle-aged people.
Race Melanoma is more common in whites than in blacks and Asians. The rate of melanoma in blacks is estimated to be 1/120 that of whites. Sex Melanoma is slightly more common in men than women (1.2:1). Melanoma is the 5th most common malignancy in men and the 6th most common malignancy in women, accounting for 5% and 4% of all new cancer case. respectively.
Overall survival. Heavy line represents CVD + IFN group; Fine line represents CVD group ; No. of death /Total No. Average survival Survival Median CVD+IFN 8/15 13.51(9.7;17.3) 12.0(9.9;14.1) CVD 7/15 10.75(9.1;12.4) 12.0(7.8;16.2)
Response rate was the highest best in CVD+IFN group (6/15)compared to CVD (4/15) , but the difference was not significant.
Combined Chemotherapy(CVD) and Biochemotherapy (CVD+IFN) in which, all showed some activity in Metastatic Melanoma.
The best responding metastatic sites were the lymph nodes all patients experienced mild adverse effects. No treatment-related deaths occurred. The median survival was 12months in CVD+IFN, CVD respectively.